Details

Autor(en) / Beteiligte

• Mastaglio, Sara
• Ruggeri, Annalisa
• Risitano, Antonio M.
• Angelillo, Piera
• Yancopoulou, Despina
• Mastellos, Dimitrios C.
• Huber-Lang, Markus
• Piemontese, Simona
• Assanelli, Andrea
• Garlanda, Cecilia
• Lambris, John D.
• Ciceri, Fabio

Titel

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Ist Teil von

• Clinical immunology (Orlando, Fla.), 2020-06, Vol.215, p.108450-108450, Article 108450

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.